Cencora (COR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
22 Jan, 2026Executive summary
Fiscal 2025 revenue reached $321.3 billion, up 9.3%, with a total shareholder return of 40%.
Strategic acquisition of Retina Consultants of America and $1 billion investment plan in U.S. distribution network through 2030.
CEO transition completed with Robert P. Mauch assuming the role; Board succession and refreshment continued.
Nearly $900 million returned to shareholders via dividends and share repurchases in fiscal 2025.
Voting matters and shareholder proposals
Shareholders will vote to elect 11 directors, approve 2025 executive compensation (say-on-pay), and ratify Ernst & Young LLP as auditor for fiscal 2026.
Board recommends voting FOR all proposals.
Shareholder proposals and director nominations for 2027 must comply with advance notice and proxy access provisions.
Board of directors and corporate governance
Board consists of 11 members, 10 of whom are independent; 8 joined in the past five years.
Board diversity: 36% female, 27% racial/ethnic diversity, average tenure 3.6 years.
Board succession planning and annual evaluations are emphasized; independent Chair appointed in October 2025.
Five standing committees, all chaired by independent directors, oversee key areas including audit, compensation, risk, finance, and governance.
Majority vote standard for director elections; proxy access and right to call special meetings for shareholders with 25% ownership.
Latest events from Cencora
- Expanded MSO ownership and robust specialty growth drive higher guidance and strategic focus.COR
Leerink Global Healthcare Conference 202610 Mar 2026 - Raised guidance and MSO strategy drive growth, with focus on specialty and de-leveraging.COR
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - All proposals passed, with strong financial growth and major strategic investments announced.COR
AGM 20269 Mar 2026 - Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08.COR
Q1 20264 Feb 2026 - Q3 revenue up 10.9% to $74.2B; adjusted EPS up 14.4%; FY2024 guidance raised.COR
Q3 20242 Feb 2026 - Virtual annual meeting to elect directors, approve pay, and ratify auditor in March 2026.COR
Proxy Filing22 Jan 2026 - 2024 EPS guidance raised; 2025 growth to slow as COVID impact normalizes, but core business remains strong.COR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - 2024 guidance increased; 2025 growth to slow as COVID impact fades, with specialty and biosimilars leading future gains.COR
Wells Fargo 2024 Healthcare Conference22 Jan 2026 - 2024 guidance raised; 2025 outlook cautious amid COVID normalization and specialty focus.COR
Baird's 2024 Global Healthcare Conference20 Jan 2026